These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25245580)

  • 1. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
    Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
    Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
    Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
    Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
    Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
    Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
    Ali MA; Elsalakawy WA
    Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
    Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
    Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
    Jiang ZP; Zhao XL; Takahashi N; Angelini S; Dubashi B; Sun L; Xu P
    Pharmacogenomics; 2017 Jan; 18(1):35-56. PubMed ID: 27991849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
    Cheng F; Cui Z; Li Q; Chen S; Li W; Zhang Y
    Int Immunopharmacol; 2024 May; 133():112090. PubMed ID: 38640718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
    Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
    Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of
    Dalle Fratte C; Polesel J; Gagno S; Posocco B; De Mattia E; Roncato R; Orleni M; Puglisi F; Guardascione M; Buonadonna A; Toffoli G; Cecchin E
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
    Zu B; Li Y; Wang X; He D; Huang Z; Feng W
    Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib.
    Dessilly G; Panin N; Elens L; Haufroid V; Demoulin JB
    Sci Rep; 2016 Jul; 6():29559. PubMed ID: 27405085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
    Rinaldi I; Nova R; Widyastuti R; Priambodo R; Instiaty I; Louisa M
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3331-3334. PubMed ID: 31759356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.